Ocugen

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines to address unmet medical needs. Its pipeline includes gene therapies for inherited retinal diseases such as retinitis pigmentosa, leber congenital amaurosis, dry age-related macular degeneration, and Stargardt disease; a fusion protein for diabetic eye diseases; regenerative cell therapies for cartilage repair; and vaccines for COVID-19 and influenza. Ocugen collaborates with research institutions and partners to advance its innovative therapies, aiming to improve patient outcomes in ophthalmology, orthopedics, and infectious diseases.